|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006826,
umls-concept:C0008976,
umls-concept:C0015385,
umls-concept:C0025202,
umls-concept:C0029246,
umls-concept:C0031001,
umls-concept:C0034656,
umls-concept:C0035168,
umls-concept:C0043237,
umls-concept:C0087111,
umls-concept:C0239307,
umls-concept:C0278627,
umls-concept:C0282461,
umls-concept:C0355642,
umls-concept:C0392752,
umls-concept:C0396670,
umls-concept:C0425358,
umls-concept:C0442711,
umls-concept:C0445202,
umls-concept:C0677582,
umls-concept:C1257890,
umls-concept:C1274040,
umls-concept:C1521808,
umls-concept:C1710136,
umls-concept:C2700615,
umls-concept:C2728259
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
1998-9-29
|
|
pubmed:abstractText |
Patients with primary cutaneous melanoma > or = 1.5 mm in thickness are at high risk of having regional micrometastases at the time of initial surgical treatment. A phase III international study was designed to evaluate whether prophylactic isolated limb perfusion (ILP) could prevent regional recurrence and influence survival.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:Di FilippoFF,
pubmed-author:EggermontA MAM,
pubmed-author:GöhlJJ,
pubmed-author:KoopsH SHS,
pubmed-author:KrementzE TET,
pubmed-author:KroonB BBB,
pubmed-author:LejeuneF JFJ,
pubmed-author:RuiterDD,
pubmed-author:SuciuSS,
pubmed-author:ThompsonJ FJF,
pubmed-author:VagliniMM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2906-12
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:9738557-Adolescent,
pubmed-meshheading:9738557-Adult,
pubmed-meshheading:9738557-Aged,
pubmed-meshheading:9738557-Aged, 80 and over,
pubmed-meshheading:9738557-Antineoplastic Agents, Alkylating,
pubmed-meshheading:9738557-Chemotherapy, Cancer, Regional Perfusion,
pubmed-meshheading:9738557-Combined Modality Therapy,
pubmed-meshheading:9738557-Disease Progression,
pubmed-meshheading:9738557-Extremities,
pubmed-meshheading:9738557-Female,
pubmed-meshheading:9738557-Humans,
pubmed-meshheading:9738557-Hypothermia, Induced,
pubmed-meshheading:9738557-Male,
pubmed-meshheading:9738557-Melanoma,
pubmed-meshheading:9738557-Melphalan,
pubmed-meshheading:9738557-Middle Aged,
pubmed-meshheading:9738557-Neoplasm Recurrence, Local,
pubmed-meshheading:9738557-Risk Factors,
pubmed-meshheading:9738557-Skin Neoplasms
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.
|
|
pubmed:affiliation |
Department of Surgical Oncology, University Hospital, Groningen, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
